Non-invasive markers for hepatic fibrosis

Area of Science:

• Hepatology
• Biomarkers
• Medical Diagnostics

Background:

• Accurate staging of liver fibrosis is essential for managing chronic liver diseases.
• Current methods for fibrosis assessment lack accuracy, reproducibility, and ease of application.
• Fibrogenesis is a complex biological process, complicating the development of reliable biomarkers.

Purpose of the Study:

• To provide a systematic overview of non-invasive techniques for liver fibrosis assessment.
• To review direct and indirect biomarker-based approaches for staging liver fibrosis.
• To cover recent advancements in non-invasive fibrosis staging methods.

Main Methods:

• Review of current non-invasive diagnostic techniques including serum biomarker assays and advanced imaging.
• Evaluation of established methods like FibroScan elastometry, APRI, and FibroTest.
• Discussion of emerging and promising non-invasive tests for liver fibrosis.

Main Results:

• Non-invasive methods, including serum biomarkers and imaging (e.g., transient elastography, MRI), are advancing.
• FibroScan, APRI, and FibroTest are gaining clinical traction, though adoption varies globally.
• Non-invasive tests can serve as pre-screening tools to identify patients for definitive liver biopsy.

Conclusions:

• Non-invasive assessment of liver fibrosis is critical for personalized management of chronic liver diseases.
• Despite challenges, advancements in biomarkers and imaging offer improved diagnostic capabilities.
• Wider adoption of validated non-invasive tests is needed to enhance clinical practice and research.